GSK plc announced that Nucala (mepolizumab) was approved in China on January 10, 2024, as a treatment for severe eosinophilic asthma, which affects approximately 46 million adults in the country. This marks it as the first targeted anti-Interleukin-5 biologic available in China, significantly reducing asthma exacerbations by 65%.